Biote recently settled its lawsuit with founder Gary Donovitz which has seen him sell the company, his 5.1 million shares and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago. These figures ...

Based on the one-year price targets offered by 5 analysts, the average target price for Biote Corp (NASDAQ:BTMD) is $9.59 with a high estimate of $12 and a low estimate of $7. The average target ...

2024 Adjusted EBITDA Guidance: Adjusted to $58 million to $61 million. Biote Corp (NASDAQ:BTMD) reported double-digit growth in both revenue and adjusted EBITDA for the third quarter of 2024.

IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness ...